MannKind Corp

MNKD

Market cap $1.64B

MannKind remains a Buy, driven by Tyvaso DPI's strong market position and Technosphere platform optionality. Tyvaso DPI continues robust growth despite Yutrepia's entry, with MNKD's Q2 share at $31 million and overall franchise strength. Recent developments include the acquisition of scPharmaceuticals, pipeline progress, and Afrezza's pediatric sBLA acceptance, supporting modest growth.

If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and DANBURY, Conn.

DANBURY, Conn. and BURLINGTON, Mass.

DANBURY, Conn. and BURLINGTON, Mass.

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving sp.

MannKind Corporation (NASDAQ:MNKD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Ross Cohen - Morgan Stanley Presentation Ross Cohen Great. Thank you all for joining us today, and welcome to the Morgan Stanley Healthcare Conference.

MannKind Corporation (NASDAQ:MNKD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 4:30 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Perfect. Thanks, everyone, for joining us.

MannKind Corporation (NASDAQ:MNKD ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst All right. Good morning, everyone.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences: